Biologics Market Size, Share and Growth Analysis 2025 to 2034

Report Id: 1729 Pages: 180 Last Updated: 19 December 2025 Format: PDF / PPT / Excel / Power BI
Share With : linkedin twitter facebook

Segmentation of Biologics Market-

Biologics Market By Source

  • Microbial
  • Mammalian
  • Others

 biologics

Biologics Market By Product

  • MABs
  • Vaccines
  • Hormones
  • Therapeutic Enzymes
  • Recombinant Proteins
  • Antisense, RNAi & Molecular Therapy
  • Blood Factors and Anticoagulants
  • Allergenic extracts
  • Human Cells and Tissues
  • Proteins
  • Gene Therapies
  • Cellular Therapies
  • Others 

Biologics Market By Disease

  • Oncology
  • Immunological Disorders
  • Cardiovascular Disorders
  • Hematological Disorders
  • Others 

Biologics Market By Manufacturing

  • Outsourced
  • In-house 

Biologics Market By Route of Administration

  • Oral
  • Others (IV and IP) 

Biologics Market By Drug Classification

  • Branded Drugs
  • Generic Drugs 

Biologics Market By Mode of Purchase

  • Prescription Drugs
  • Over The Counter (OTC) Drugs 

Biologics Market By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Biologics Market By Region-

North America-

  • The US
  • Canada

Europe-

  • Germany
  • The UK
  • France
  • Italy
  • Spain
  • Rest of Europe

Asia-Pacific-

  • China
  • Japan
  • India
  • South Korea
  • Southeast Asia
  • Rest of Asia Pacific

Latin America-

  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America

 Middle East & Africa-

  • GCC Countries
  • South Africa
  • Rest of the Middle East and Africa

Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions

Chapter 2. Executive Summary

Chapter 3. Global Biologics Market Snapshot

Chapter 4. Global Biologics Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Route of Administration Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis

Chapter 5. Market Segmentation 1: by Source Estimates & Trend Analysis
5.1. by Source & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Source:

5.2.1. Microbial
5.2.2. Mammalian
5.2.3. Others

Chapter 6. Market Segmentation 2: by Product Estimates & Trend Analysis
6.1. by Product & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Product:

6.2.1. MABs
6.2.2. Vaccines
6.2.3. Hormones
6.2.4. Therapeutic Enzymes
6.2.5. Recombinant Proteins
6.2.6. Antisense, RNAi & Molecular Therapy
6.2.7. Blood Factors and Anticoagulants
6.2.8. Allergenic extracts
6.2.9. Human Cells and Tissues
6.2.10. Proteins
6.2.11. Gene Therapies
6.2.12. Cellular Therapies
6.2.13. Others

Chapter 7. Market Segmentation 3: by Disease Estimates & Trend Analysis
7.1. by Disease & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Disease:

7.2.1. Oncology
7.2.2. Immunological Disorders
7.2.3. Cardiovascular Disorders
7.2.4. Hematological Disorders
7.2.5. Others

Chapter 8. Market Segmentation 4: by Manufacturing Estimates & Trend Analysis
8.1. by Manufacturing & Market Share, 2024 & 2034
8.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Manufacturing:

8.2.1. Outsourced
8.2.2. In-house

Chapter 9. Market Segmentation 5: by Distribution Channel Estimates & Trend Analysis
9.1. by Distribution Channel & Market Share, 2024 & 2034
9.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Distribution Channel:

9.2.1. Hospital Pharmacies
9.2.2. Retail Pharmacies
9.2.3. Online Pharmacies

Chapter 10. Market Segmentation 6: by Route of Administration Estimates & Trend Analysis
10.1. by Route of Administration& Market Share, 2024 & 2034
10.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Route of Administration:

10.2.1. Oral
10.2.2. Others (IV and IP)

Chapter 11. Market Segmentation 7: by Drug Classification Estimates & Trend Analysis
11.1. by Drug Classification & Market Share, 2024 & 2034
11.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Drug Classification:

11.2.1. Branded Drugs
11.2.2. Generic Drugs

Chapter 12. Market Segmentation 8: by Mode of Purchase Estimates & Trend Analysis
12.1. by Mode of Purchase & Market Share, 2024 & 2034
12.2. Market Size (Value (US$ Mn)) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Mode of Purchase:

12.2.1. Prescription Drugs
12.2.2. Over The Counter (OTC) Drugs

Chapter 13. Biologics Market Segmentation 9: Regional Estimates & Trend Analysis

13.1. North America

13.1.1. North America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Source, 2021-2034
13.1.2. North America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
13.1.3. North America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2021-2034
13.1.4. North America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Manufacturing, 2021-2034
13.1.5. North America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
13.1.6. North America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
13.1.7. North America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Drug Classification, 2021-2034
13.1.8. North America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Mode of Purchase, 2021-2034
13.1.9. North America Biologics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

13.2. Europe

13.2.1. Europe Biologics Market Revenue (US$ Million) Estimates and Forecasts by Source, 2021-2034
13.2.2. Europe Biologics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
13.2.3. Europe Biologics Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2021-2034
13.2.4. Europe Biologics Market Revenue (US$ Million) Estimates and Forecasts by Manufacturing, 2021-2034
13.2.5. Europe Biologics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
13.2.6. Europe Biologics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
13.2.7. Europe Biologics Market Revenue (US$ Million) Estimates and Forecasts by Drug Classification, 2021-2034
13.2.8. Europe Biologics Market Revenue (US$ Million) Estimates and Forecasts by Mode of Purchase, 2021-2034
13.2.9. Europe Biologics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

13.3. Asia Pacific

13.3.1. Asia Pacific Biologics Market Revenue (US$ Million) Estimates and Forecasts by Source, 2021-2034
13.3.2. Asia Pacific Biologics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
13.3.3. Asia-Pacific Biologics Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2021-2034
13.3.4. Asia Pacific Biologics Market Revenue (US$ Million) Estimates and Forecasts by Manufacturing, 2021-2034
13.3.5. Asia Pacific Biologics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
13.3.6. Asia Pacific Biologics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
13.3.7. Asia Pacific Biologics Market Revenue (US$ Million) Estimates and Forecasts by Drug Classification, 2021-2034
13.3.8. Asia Pacific Biologics Market Revenue (US$ Million) Estimates and Forecasts by Mode of Purchase, 2021-2034
13.3.9. Asia Pacific Biologics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

13.4. Latin America

13.4.1. Latin America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Source, 2021-2034
13.4.2. Latin America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
13.4.3. Latin America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2021-2034
13.4.4. Latin America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Manufacturing, 2021-2034
13.4.5. Latin America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
13.4.6. Latin America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
13.4.7. Latin America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Drug Classification, 2021-2034
13.4.8. Latin America Biologics Market Revenue (US$ Million) Estimates and Forecasts by Mode of Purchase, 2021-2034
13.4.9. Latin America Biologics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

13.5. Middle East & Africa

13.5.1. Middle East & Africa Biologics Market Revenue (US$ Million) Estimates and Forecasts by Source, 2021-2034
13.5.2. Middle East & Africa Biologics Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
13.5.3. Middle East & Africa Biologics Market Revenue (US$ Million) Estimates and Forecasts by Disease, 2021-2034
13.5.4. Middle East & Africa Biologics Market Revenue (US$ Million) Estimates and Forecasts by Manufacturing, 2021-2034
13.5.5. Middle East & Africa Biologics Market Revenue (US$ Million) Estimates and Forecasts by Distribution Channel, 2021-2034
13.5.6. Middle East & Africa Biologics Market Revenue (US$ Million) Estimates and Forecasts by Route of Administration, 2021-2034
13.5.7. Middle East & Africa Biologics Market Revenue (US$ Million) Estimates and Forecasts by Drug Classification, 2021-2034
13.5.8. Middle East & Africa Biologics Market Revenue (US$ Million) Estimates and Forecasts by Mode of Purchase, 2021-2034
13.5.9. Middle East & Africa Biologics Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034

Chapter 14. Competitive Landscape

14.1. Major Mergers and Acquisitions/Strategic Alliances

14.2. Company Profiles


14.2.1. Abbvie Inc.
14.2.2. Amgen
14.2.3. AstraZeneca
14.2.4. Bayer AG
14.2.5. Celltrion Inc.
14.2.6. Addgene
14.2.7. Eli Lilly & Company
14.2.8. F. Hoffmann-La Roche Ltd
14.2.9. GSK group of companies
14.2.10. Johnson & Johnson Services, Inc
14.2.11. Merck & Co. Inc
14.2.12. Novartis AG
14.2.13. Novo Nordisk A/S
14.2.14. Pfizer Inc.
14.2.15. Precision Biologics, Inc.
14.2.16. Samsung Biologics
14.2.17. Sanofi
14.2.18. Other Prominent Players

Research Design and Approach

This study employed a multi-step, mixed-method research approach that integrates:

  • Secondary research
  • Primary research
  • Data triangulation
  • Hybrid top-down and bottom-up modelling
  • Forecasting and scenario analysis

This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.

Secondary Research

Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.

Sources Consulted

Secondary data for the market study was gathered from multiple credible sources, including:

  • Government databases, regulatory bodies, and public institutions
  • International organizations (WHO, OECD, IMF, World Bank, etc.)
  • Commercial and paid databases
  • Industry associations, trade publications, and technical journals
  • Company annual reports, investor presentations, press releases, and SEC filings
  • Academic research papers, patents, and scientific literature
  • Previous market research publications and syndicated reports

These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.

Secondary Research

Primary Research

Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.

Stakeholders Interviewed

Primary interviews for this study involved:

  • Manufacturers and suppliers in the market value chain
  • Distributors, channel partners, and integrators
  • End-users / customers (e.g., hospitals, labs, enterprises, consumers, etc., depending on the market)
  • Industry experts, technology specialists, consultants, and regulatory professionals
  • Senior executives (CEOs, CTOs, VPs, Directors) and product managers

Interview Process

Interviews were conducted via:

  • Structured and semi-structured questionnaires
  • Telephonic and video interactions
  • Email correspondences
  • Expert consultation sessions

Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.

Data Processing, Normalization, and Validation

All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.

The data validation process included:

  • Standardization of units (currency conversions, volume units, inflation adjustments)
  • Cross-verification of data points across multiple secondary sources
  • Normalization of inconsistent datasets
  • Identification and resolution of data gaps
  • Outlier detection and removal through algorithmic and manual checks
  • Plausibility and coherence checks across segments and geographies

This ensured that the dataset used for modelling was clean, robust, and reliable.

Market Size Estimation and Data Triangulation

Bottom-Up Approach

The bottom-up approach involved aggregating segment-level data, such as:

  • Company revenues
  • Product-level sales
  • Installed base/usage volumes
  • Adoption and penetration rates
  • Pricing analysis

This method was primarily used when detailed micro-level market data were available.

Bottom Up Approach

Top-Down Approach

The top-down approach used macro-level indicators:

  • Parent market benchmarks
  • Global/regional industry trends
  • Economic indicators (GDP, demographics, spending patterns)
  • Penetration and usage ratios

This approach was used for segments where granular data were limited or inconsistent.

Hybrid Triangulation Approach

To ensure accuracy, a triangulated hybrid model was used. This included:

  • Reconciling top-down and bottom-up estimates
  • Cross-checking revenues, volumes, and pricing assumptions
  • Incorporating expert insights to validate segment splits and adoption rates

This multi-angle validation yielded the final market size.

Forecasting Framework and Scenario Modelling

Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.

Forecasting Methods

  • Time-series modelling
  • S-curve and diffusion models (for emerging technologies)
  • Driver-based forecasting (GDP, disposable income, adoption rates, regulatory changes)
  • Price elasticity models
  • Market maturity and lifecycle-based projections

Scenario Analysis

Given inherent uncertainties, three scenarios were constructed:

  • Base-Case Scenario: Expected trajectory under current conditions
  • Optimistic Scenario: High adoption, favourable regulation, strong economic tailwinds
  • Conservative Scenario: Slow adoption, regulatory delays, economic constraints

Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.

Name field cannot be blank!
Email field cannot be blank!(Use email format)
Designation field cannot be blank!
Company field cannot be blank!
Contact No field cannot be blank!
Message field cannot be blank!
8566
Security Code field cannot be blank!

Frequently Asked Questions

Biologics Market Size is valued at USD 426.1 Bn in 2024 and is predicted to reach USD 890.2 Bn by the year 2034

Global Biologics Market expected to grow at a 7.8% CAGR during the forecast period for 2025-2034

Samsung BioLogics; Amgen; Novo Nordisk A/S; AbbVie Inc.; Sanofi; Pfizer Inc.; Inc.; GSK group of companies; Merck & Co., Celltrion; Precision Biologic

Source, Product, Disease, Manufacturing, Route of Administration, Drug Classification and Mode of Purchase, Distribution Channel are the key segments

North America region is leading the Biologics Market.

Report License Selection

Determine the Appropriate License for your Report

Get Sample Report Enquiry Before Buying